Decentralized trials

Castor announced transformative growth with anticipated topline acceleration driven by the company’s momentous US market expansion

Castor advisor Craig Lipset, suggests that you consider DCT technology as three separate tiers. Learn more about these tiers and get started with DCT in 2022 with these pro tips.

Researchers are looking to incorporate remote technologies into medical device trials for a wide range of device classifications. This article explores current regulations for various classes of medical devices and how this will impact the need for participants to visit research sites throughout the trial.

Medical device regulations in the EU have recently undergone a major overhaul. Learn the key tenets of MDR by device classification in this fact sheet, and what checklist items must be addressed to be fully compliant.

In this whitepaper, we will look at how EDC, eConsent, ePRO, and APIs enable researchers to easily conduct decentralized and hybrid clinical trials.

Castor’s DCT platform helping medical device trials achieve compliance with patient-focused technology  Driving innovation for medical device clinical…

The Castor team is thrilled to see an increasing emphasis on diversity of race, gender, and even geography amongst clinical trial participants. Critically, experts call for not just increased diversity on a statistical basis, but that the studied population is representative of the distribution of the disease.

Thought leaders from Castor and Lightship discuss opportunities that will help researchers develop a more successful overall strategy for their patient enrollment.

Download this eBook to gain a comprehensive overview of eConsent, how it satisfies global regulatory requirements and key considerations for ethics board approval.

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.